BLCO — Bausch + Lomb Corporation
$17.62+0.23%
Last close: · regular session
Last 60 sessions
BLCO closed at $17.62 (+0.23%) on Oct 27, 2026. Float: 46.4M shares. Latest SEC filing: 8-K on Oct 28, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for BLCO in the TickerWise workspace.
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Company profile
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: CA
- Exchange: NYSE
- Employees: 13,500
- Website: https://www.bausch.com
Latest SEC filings for BLCO
Latest BLCO news
- Bausch + Lomb Q3 2026 Earnings Preview Read article
- Bausch + Lomb makes progress on development of oral treatment for dry AMD Read article
- Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 Read article
- BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser Read article
- Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others Read article
- A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story Read article
- Bausch + Lomb Corporation Investigated by the Portnoy Law Firm Read article
- Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.